Incyte says Opzelura cream sustains disease control through 24 weeks in Phase 3 TRuE-AD4 trial

Incyte Corporation

Incyte Corporation

INCY

0.00
  • Incyte reported final 24-week Phase 3 TRuE-AD4 data for Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis, with results presented at 2026 EADV Symposium.
  • Patients who responded early and stayed on as-needed treatment largely maintained disease control through 24 weeks, supporting durability of effect in this population.
  • Safety profile remained consistent over the study period, with few local reactions reported and no new safety concerns flagged.
  • Data underpin a Type-II variation filing in EU for ruxolitinib cream 1.5% in adults with moderate atopic dermatitis, with regulatory feedback expected in 1H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202605070850BIZWIRE_USPR_____20260507_BW606978) on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.